Cargando…

Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with few treatment options. N-acetylcysteine (NAC) is a well-tolerated, inexpensive treatment with antioxidant and anti-fibrotic properties. The National Heart, Lung, and Blood Institute (NHLBI)-sponsored PANTHER (Predniso...

Descripción completa

Detalles Bibliográficos
Autores principales:	Podolanczuk, Anna J., Kim, John S., Cooper, Christopher B., Lasky, Joseph A., Murray, Susan, Oldham, Justin M., Raghu, Ganesh, Flaherty, Kevin R., Spino, Cathie, Noth, Imre, Martinez, Fernando J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746571/ https://www.ncbi.nlm.nih.gov/pubmed/36514019 http://dx.doi.org/10.1186/s12890-022-02281-8

Ejemplares similares

Design and rationale of a multi-center, pragmatic, open-label randomized trial of antimicrobial therapy – the study of clinical efficacy of antimicrobial therapy strategy using pragmatic design in Idiopathic Pulmonary Fibrosis (CleanUP-IPF) clinical trial
por: Anstrom, Kevin J., et al.
Publicado: (2020)

Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry
por: Snyder, Laurie D, et al.
Publicado: (2020)

Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort
por: Todd, Jamie L., et al.
Publicado: (2020)

Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry Cohort
por: Todd, Jamie L., et al.
Publicado: (2022)

Correction to: Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry Cohort
por: Todd, Jamie L., et al.
Publicado: (2022)

Antibody-mediated depletion of CCR10(+)EphA3(+) cells ameliorates fibrosis in IPF
por: Hohmann, Miriam S., et al.
Publicado: (2021)

Rationale for and design of the Idiopathic Pulmonary Fibrosis–PRospective Outcomes (IPF-PRO) registry
por: O'Brien, Emily C, et al.
Publicado: (2016)

Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry
por: Todd, Jamie L., et al.
Publicado: (2019)

Gastroesophageal reflux and antacid therapy in IPF: analysis from the Australia IPF Registry
por: Jo, Helen E., et al.
Publicado: (2019)

Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomised placebo-controlled INMARK®trial
por: Maher, Toby M, et al.
Publicado: (2018)

Development of the ATAQ-IPF: a tool to assess quality of life in IPF
por: Swigris, Jeffrey J, et al.
Publicado: (2010)

Six-SOMAmer Index Relating to Immune, Protease and Angiogenic Functions Predicts Progression in IPF
por: Ashley, Shanna L., et al.
Publicado: (2016)

Identification of a unique temporal signature in blood and BAL associated with IPF progression
por: Norman, Katy C., et al.
Publicado: (2020)

Precision Family Spirit: a pilot randomized implementation trial of a precision home visiting approach with families in Michigan—trial rationale and study protocol
por: Ingalls, Allison, et al.
Publicado: (2021)

Recommendations on treatment for IPF
por: Behr, Jürgen, et al.
Publicado: (2013)

Serum Progranulin Level Might Differentiate Non-IPF ILD from IPF
por: Tóth, Nóra Melinda, et al.
Publicado: (2023)

Reply to Spek and Duitman
por: Oldham, Justin M., et al.
Publicado: (2023)

Design and Rationale of a Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study Evaluating Dociparstat in Acute Lung Injury Associated with Severe COVID-19
por: Lasky, Joseph A., et al.
Publicado: (2020)

PolyvasculaR Evaluation for Cognitive Impairment and vaScular Events (PRECISE)—a population-based prospective cohort study: rationale, design and baseline participant characteristics
por: Pan, Yuesong, et al.
Publicado: (2020)

Reply to Lescoat et al. and to Khamis et al.
por: Adegunsoye, Ayodeji, et al.
Publicado: (2019)

Using an Electronic Decision Support Tool to Reduce Inappropriate Polypharmacy and Optimize Medicines: Rationale and Methods
por: Young, Amber, et al.
Publicado: (2016)

A feasibility, randomised controlled trial of a complex breathlessness intervention in idiopathic pulmonary fibrosis (BREEZE-IPF): study protocol
por: Wright, Caroline, et al.
Publicado: (2019)

Processes, contexts, and rationale for disinvestment: a protocol for a critical interpretive synthesis
por: Wilson, Michael G, et al.
Publicado: (2014)

Highlights of HRCT imaging in IPF
por: Sverzellati, N
Publicado: (2013)

IPF - Idiopathic Pulmonary Fibrosis
Publicado: (2019)

The role of neutrophils in the pathogenesis of IPF
por: Jegal, Yangjin
Publicado: (2022)

Investigating significant health trends in idiopathic pulmonary fibrosis (INSIGHTS-IPF): rationale, aims and design of a nationwide prospective registry
por: Behr, Juergen, et al.
Publicado: (2014)

HIV-associated nephropathy: Protocol and rationale for an exploratory genotype-phenotype study in a sub-Saharan African population
por: Yusuf, Aminu Abba, et al.
Publicado: (2021)

Rationale and Design of the ORCCA (Outcomes Registry for Cardiac Conditions in Athletes) Study
por: Moulson, Nathaniel, et al.
Publicado: (2023)

A 2D and 3D cell culture protocol to study O-GlcNAc in sphingosine-1-phosphate mediated fibroblast contraction
por: Morales, Murielle M., et al.
Publicado: (2022)

Rapidly non-ipf progressive fibrosing interstitial lung disease: a phenotype with an ipf-like behavior
por: Khine, Ngu, et al.
Publicado: (2020)

IPF clinical trial design and endpoints
por: Nathan, Steven D., et al.
Publicado: (2014)

Mitochondrial Quality Control in COPD and IPF
por: Hara, Hiromichi, et al.
Publicado: (2018)

Idiopathic Pulmonary Fibrosis (IPF): An Overview
por: Barratt, Shaney L., et al.
Publicado: (2018)

The Role of Immunity and Inflammation in IPF Pathogenesis
por: Butler, Marcus W., et al.
Publicado: (2018)

Senescent Cells in IPF: Locked in Repair?
por: Meiners, Silke, et al.
Publicado: (2020)

IPF in Saudi Arabia: Lessons for all
por: Nathan, Steven D.
Publicado: (2020)

Microbiota and IPF: hidden and detected relationships
por: Fabbrizzi, Alessio, et al.
Publicado: (2021)

Radiological and Physiological Predictors of IPF Mortality
por: Kishaba, Tomoo, et al.
Publicado: (2021)

Moving senolytics closer to the clinic in IPF
por: Kramer, Daniel, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6r0lqd7f97f470idrck1nrmdfe